SLC22A13

Across TCGA pan-cancer cohorts, SLC22A13 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC22A13 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher SLC22A13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC22A13 expression acts as an unfavorable survival marker.

THYM, KICH, and LUSC are the cancer types where SLC22A13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUSC	OS	Median	All	0.477	0.763	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC22A13–THYM (OS)

Open the THYM breakdown →